About the Authors
- Otto O. Yang
-
Contributed equally to this work with: Otto O. Yang, F. Javier Ibarrondo, Peter A. Anton
* E-mail: OYang@mednet.ucla.edu
Affiliations Department of Medicine and University of California Los Angeles AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America, Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America, AIDS Healthcare Foundation, Los Angeles, California, United States of America
- F. Javier Ibarrondo
-
Contributed equally to this work with: Otto O. Yang, F. Javier Ibarrondo, Peter A. Anton
Affiliation Department of Medicine and University of California Los Angeles AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America
- Charles Price
-
Affiliation Department of Medicine and University of California Los Angeles AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America
- Lance E. Hultin
-
Affiliation Department of Medicine and University of California Los Angeles AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America
- Julie Elliott
-
Affiliation Department of Medicine and University of California Los Angeles AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America
- Patricia M. Hultin
-
Affiliation Department of Medicine and University of California Los Angeles AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America
- Roger Shih
-
Affiliation Department of Medicine and University of California Los Angeles AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America
- Mary Ann Hausner
-
Affiliation Department of Medicine and University of California Los Angeles AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America
- Hwee L. Ng
-
Affiliation Department of Medicine and University of California Los Angeles AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America
- Jennifer Hoffman
-
Affiliation Department of Medicine and University of California Los Angeles AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America
- Beth D. Jamieson
-
Affiliation Department of Medicine and University of California Los Angeles AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America
- Peter A. Anton
-
Contributed equally to this work with: Otto O. Yang, F. Javier Ibarrondo, Peter A. Anton
Affiliation Department of Medicine and University of California Los Angeles AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America
Competing Interests
Sanofi Pasteur specifically provided the GMP vaccine and placebo, and performed the ELISAs for anti-Canarypox antibodies. Otherwise, they provided no financial support related to this study. Requests for vCP205 vaccine and canarypox ELISA reagents would need to be directed to Sanofi Pasteur, but otherwise this does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: OY FI JE BJ PA. Performed the experiments: FI LH JE PH RS MH HN. Analyzed the data: OY FI LH JE JH BJ PA. Contributed reagents/materials/analysis tools: CP PA. Wrote the paper: OY FI JH BJ PA. Clinical trial administrative management: CP.